EICHORPublic-registry site landscape for NCT03938792, “Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B”, a Hemophilia A study sponsored by Pfizer. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03938792 (registry record) |
| Study title | Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B |
| Official title | An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis |
| Sponsor | Pfizer |
| Condition(s) | Hemophilia A; Hemophilia B |
| Phase | PHASE3 |
| Listed sites | 62 |
| Site countries | United States, Bulgaria, Canada, China, Croatia, France, Hong Kong, India, Italy, Japan, Mexico, Oman |
Patient-friendly overview of this study: eichor.com/study/NCT03938792.
Eichor generates a preliminary site-risk snapshot for NCT03938792 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Hemophilia A trials
More from Pfizer
← Eichor home · All tracked trials · Hemophilia A studies · Weekly briefs
